Investor Relations
Latest Financial Results
Q1 2025
Quarter Ended Mar 31, 2025
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2024
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
IR Contacts
Company
Aurinia Pharmaceuticals Inc.
#140, 14315 – 118 Avenue
Edmonton, AB T5L 4S6
Canada
T: +1 (250) 744-2487
F: +1 (250) 708-4345
Investor Relations
Andrea Christopher
Executive Director, Corporate Communications & Investor Relations
achristopher@auriniapharma.com
General inquiries can also be sent to
ir@auriniapharma.com
Transfer Agent
Computershare Trust Company of Canada
Shareholder Services Dept.
100 University Avenue
9th Floor
Toronto, ON M5J 2Y1
Canada
T: +1-514-982-7555
service@computershare.com
https://www.computershare.com
